$23.97
-0.43 (-1.76%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where SPTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 3 tracked-famous managers (CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, Squarepoint Ops LLC) · FINRA short interest 30.8 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)NCT07161700Safety and tolerability assessments based on Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and validated clinical scales and proceduresOpen-label · Treatment | Phase 2 | Enrolling by invitation | Drug: SPT-300 | Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress | 360 | May 2027 | ≤ 285 d | 2026-08-17 |
| A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)NCT07065240Change From Baseline to Day 42 in Hamilton Depression Rating Scale-17 (HAM-D-17) Total ScoreRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: SPT-300, Placebo | Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress | 360 | Mar 2027 | ≤ 224 d | 2026-08-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19